Price
No data yet.
Social Signal Score
Revenue
$5.84M-19.48%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Matthew C. Kapusta
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 221
- Beta
- 0.94
- Country
- NL
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.07
Financials
Revenue
$5.84M-19.5%Net Income
$-81.06MEBITDA
$-69.99MFree Cash Flow
$-29.05MEPS (diluted)
$-1.22Shares Outstanding (diluted)
66.24M+163.5%Operating Expenses
$51.33MCash & Debt
$810.34MRevenue by Segment (annual)
$16.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.10M | $-198.97M | $-3.46 |
| 2024 | $27.12M | $-239.56M | $-4.92 |
| 2023 | $15.84M | $-308.48M | $-6.47 |
| 2022 | $106.48M | $-126.79M | $-2.71 |
| 2021 | $524.00M | $329.59M | $7.17 |
| 2020 | $37.51M | $-125.02M | $-2.81 |
| 2019 | $7.28M | $-124.20M | $-3.20 |
| 2018 | $11.28M | $-83.30M | $-2.34 |
| 2017 | $13.11M | $-80.39M | $-2.98 |
| 2016 | $25.10M | $-73.37M | $-2.93 |
| 2015 | $10.30M | $-78.15M | $-3.54 |
| 2014 | $5.70M | $-45.04M | $-2.63 |
| 2013 | $4.06M | $-37.03M | $-2.10 |
| 2012 | $0.00 | $-19.46M | $-1.11 |
Valuation
QUREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (2)
- Newszacks.com·7h ago·Neutral
QURE Submits Application for Gene Therapy for Huntington's Disease QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
View source ↗ - Newsbenzinga.com·1d ago·Negative
uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says On Wednesday, uniQure N.V. (NASDAQ:QURE) submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington's disease.
View source ↗
Earnings
Mon, Nov 9(in 2 months)
Consensus estimate $-0.92 per share
Typical surprise +3.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-1.22 vs $-0.82miss
- Tue, May 5$-0.85 vs $-0.88beat
- Mon, Mar 2$-0.56 vs $-0.93beat
- Mon, Nov 10$-1.38 vs $-0.85miss
- Tue, Jul 29$-0.69 vs $-0.89beat
- Fri, May 9$-0.82 vs $-1.07beat
Estimates and results for QURE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QURE officers and directors.
- Bought
- —
- Sold
- $18.7m
0 trades
44 trades
- Kapusta Matthew Csold
- Kapusta Matthew Csold
- Kapusta Matthew Csold
- Abi-saab Walidsold
- Abi-saab Walidsold
- Kaye Jacksold
- Kaye Jacksold
- Abi-saab Walidsold
56 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.